Skip to Content

Tilray Brands Inc TLRY

Morningstar Rating
$1.88 +0.03 (1.62%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

TLRY is trading at a 788% premium.
Price
$1.88
Fair Value
$5.00
Uncertainty
Very High
1-Star Price
$7.90
5-Star Price
$6.00
Economic Moat
Khgl
Capital Allocation
Qfprxndyp

Bulls Say, Bears Say

Bulls

Tilray's better financial health and profitability lead compared with Canadian peers positions it to lead its home market.

Bears

The existence of the illicit market limits the potential price increases Tilray can push through to consumers.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLRY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$1.85
Day Range
$1.831.88
52-Week Range
$1.603.40
Bid/Ask
$1.86 / $1.87
Market Cap
$1.55 Bil
Volume/Avg
12.2 Mil / 23.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.81
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.08%

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Value
Total Number of Employees
1,600

Competitors

Valuation

Metric
TLRY
CRON
CGC
Price/Earnings (Normalized)
1,482.16
Price/Book Value
0.430.861.60
Price/Sales
1.819.872.21
Price/Cash Flow
Price/Earnings
TLRY
CRON
CGC

Financial Strength

Metric
TLRY
CRON
CGC
Quick Ratio
0.9626.511.09
Current Ratio
1.9228.191.58
Interest Coverage
−4.39−3.63
Quick Ratio
TLRY
CRON
CGC

Profitability

Metric
TLRY
CRON
CGC
Return on Assets (Normalized)
−1.42%−0.28%−17.78%
Return on Equity (Normalized)
−1.82%−0.29%−46.87%
Return on Invested Capital (Normalized)
−0.92%−4.97%−16.41%
Return on Assets
TLRY
CRON
CGC
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - Specialty & Generic Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
CkhbnzlcgpZzx$81.7 Bil
Merck KGaA ADR
MKKGY
QldkzfgmkWmcxzz$72.9 Bil
Haleon PLC ADR
HLN
RhrkdwdgXqtcz$39.8 Bil
Dr Reddy's Laboratories Ltd ADR
RDY
TkglhqhxGqq$13.4 Bil
Viatris Inc
VTRS
PqpxcvlfMqnr$13.4 Bil
Catalent Inc
CTLT
MzgjhmdClfwxgz$10.4 Bil
Perrigo Co PLC
PRGO
HlkxxxtzYdqv$3.7 Bil
Prestige Consumer Healthcare Inc
PBH
RspqwbnkkGgffzl$3.5 Bil
Curaleaf Holdings Inc
CURLF
WmjpmlyvdDqbpy$3.1 Bil
Green Thumb Industries Inc
GTBIF
WlssbvkhTmhq$2.8 Bil

Sponsor Center